Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine and Psychedelics Clinical IP
Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine and Psychedelics Clinical IP
Toronto, Ontario--(Newsfile Corp. - March 16, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FWB: 4960) ("Braxia", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announces that Irwin Naturals Inc. ("Irwin") has terminated the non-binding amended and restated letter of intent ("LOI") for a business combination between Irwin and Braxia (the "Proposed Transaction"). Full details of the Proposed Transaction were contained in the Company's news release dated January 27, 2023.
安大略省多伦多--(Newsfile Corp.-2023年3月16日)-BraxiaScience Corp.(CSE：BRAX)(场外交易代码：BRAXF)(FWB：4960)(以下简称“本公司”)宣布，Irwin Naturals Inc.(以下简称“Irwin”)已经终止了Irwin和Braxia二家企业合并的非约束性修订和重述意向书(“意向书”)，该意向书是一家医疗研究和远程医疗公司，提供创新的氯胺酮和裸盖菇素治疗抑郁症及相关疾病的药物。拟议交易的全部细节包含在该公司日期为2023年1月27日的新闻稿中。
"We are disappointed with the decision by Irwin and that we could not complete the transaction," said Dr. Roger McIntyre, CEO of Braxia. "The Braxia team remains well positioned as global leaders in depression and ketamine research, as ranked by Expertscape, with high quality, trusted clinics and a telemedicine platform launched in the United States."
BraxiaCEO罗杰·麦金太尔博士表示：“我们对欧文的决定感到失望，我们无法完成交易。”根据Expertscape的排名，Braxia团队仍然是抑郁症和氯胺酮研究领域的全球领先者，拥有高质量、值得信赖的诊所和在美国推出的远程医疗平台。
Braxia Maintains its Strategic Clinical IP, Telemedicine and Research Infrastructure Assets and Capabilities
Braxia保持其战略临床IP、远程医疗和研究基础设施的资产和能力
Braxia and its clinical management team remain market leaders in the research and delivery of mental health novel treatments. The Company is pleased to maintain its strategic assets across three important business verticals - including its Clinical Operations in Canada, a US-based telemedicine platform and International Clinical Research Infrastructure.
Braxia及其临床管理团队在精神健康新疗法的研究和提供方面仍然是市场领先者。该公司很高兴维持其在三个重要业务垂直领域的战略资产，包括其在加拿大的临床业务、总部设在美国的远程医疗平台和国际临床研究基础设施。
"Over the last year, we have accomplished several key milestones in mental health research and development. We are moving forward with our current strategy of developing our clinical operations in Canada, currently providing Ketamine and Psilocybin treatments, while building out our strategic and highly scalable telemedicine business with KetaMD, Inc. in the US. We are also actively building our CRO business providing capabilities and research services to pharmaceutical companies looking to quickly develop or co-develop IP in novel therapeutics", concluded Dr. McIntyre.
麦金泰尔博士总结道：“在过去的一年里，我们在精神健康研究和开发方面取得了几个关键的里程碑。我们正在推进我们目前在加拿大发展临床业务的战略，目前提供氯胺酮和裸盖菇素治疗，同时与美国的KetaMD，Inc.建立我们的战略性和高度可扩展的远程医疗业务。我们还在积极建立我们的CRO业务，为希望快速开发或共同开发新型疗法知识产权的制药公司提供能力和研究服务。”
The Company remains committed to evaluating a number of potential strategic opportunities to create shareholder value in the mental health industry which continues to evolve and consolidate.
公司仍致力于评估一些潜在的战略机会，以在不断发展和巩固的精神健康行业创造股东价值。
About Braxia Scientific Corp.
布拉夏科学公司简介
Braxia is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Braxia also launched its U.S. based end-to-end telemedicine platform KetaMD, that utilizes leading technology to provide access to safe, affordable, and potentially life-changing at-home ketamine treatments for people living with depression and related mental health conditions. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatments in-person and virtually for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary the Canadian Rapid Treatment Center of Excellence Inc., carrying on business as Braxia Health, the Company operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.
Braxia是一家医学研究和远程医疗公司，拥有为抑郁症和相关疾病患者提供创新型氯胺酮治疗的诊所。Braxia还推出了其在美国的端到端远程医疗平台KetaMD，该平台利用领先的技术为患有抑郁症和相关精神健康问题的患者提供安全、负担得起、可能改变生活的家庭氯胺酮治疗。通过其医疗解决方案，Braxia旨在减轻以大脑为基础的疾病的疾病负担，如严重的抑郁症等。Braxia主要专注于(I)拥有和经营多学科诊所，提供面对面和虚拟的精神健康障碍治疗，以及(Ii)与发现和商业化新药和递送方法有关的研究活动。布拉夏寻求从其知识产权开发平台开发氯胺酮及其衍生物和其他迷幻产品。通过其全资子公司加拿大卓越快速治疗中心，该公司以BraxiaHealth的名义经营业务，在密西索加、多伦多、基奇纳-滑铁卢、渥太华和蒙特利尔经营多学科社区诊所，为抑郁症提供快速有效的治疗。
FOR FURTHER INFORMATION PLEASE CONTACT:
欲了解更多信息，请联系：
Braxia Scientific Corp.
Tel: 416-762-2138
Email: info@braxiascientific.com
Website:
布拉夏科学公司
电话电话：416-762-2138
电子邮件电子邮件：info@braxiascientific.com
网站：
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
CSE未对本新闻稿的准确性或充分性进行审查，也不承担任何责任。
Forward-looking Information Cautionary Statement
前瞻性信息警示声明
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."
本新闻稿包含符合适用证券法的前瞻性陈述。所有不是历史事实、未来估计、计划、计划、预测、预测、目标、假设、预期或对未来业绩的信念的陈述都是“前瞻性陈述”。
Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression, the potential for ketamine or other psychedelics to treat other mental health conditions, the ability of telemedicine to address the unmet need for mental health disorders or expand or accelerate the growth of Braxia, the fact that the Proposed Transaction will not be completed, the Company's strategy of developing its clinical operations in Canada while building out its strategic and highly scalable telemedicine business with KetaMD, Inc. in the United States and the build out of Company's CRO business of providing capabilities and research services to pharmaceutical companies. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.
前瞻性陈述包括：基于氯胺酮的抑郁症治疗的预期承诺；氯胺酮或其他迷幻剂治疗其他精神健康疾病的潜力；远程医疗解决未得到满足的精神健康障碍的需求或扩大或加速布拉夏的增长的能力；拟议的交易将无法完成的事实；该公司在加拿大发展其临床业务的战略，同时与美国的KetaMD公司建立其战略和高度可扩展的远程医疗业务，以及公司向制药公司提供能力和研究服务的CRO业务的扩大。此类前瞻性表述涉及已知和未知的风险、不确定性和其他因素，可能导致实际结果、事件或发展与此类前瞻性表述明示或暗示的任何未来结果、事件或发展大相径庭。除其他外，这些风险和不确定性包括氯胺酮、裸盖菇素和其他迷幻剂未能提供预期的健康益处和意想不到的副作用，依赖于获得和维持监管批准，包括获得和续签联邦、省、市、地方或其他许可证，以及从事后来根据国内或国际法可能被认定为非法的活动。氯胺酮和裸盖菇素目前分别是《受控药物和物质法》(《受控药物和物质法》，S.C.1996，c.19)规定的附表一和附表三的受控物质，根据《受控药物和物质法》，在没有处方或法律豁免的情况下拥有这类物质是刑事犯罪。加拿大卫生部尚未批准裸盖菇素作为任何适应症的药物，但氯胺酮是法律允许用于治疗某些心理疾病的药物。在加拿大，在没有处方的情况下拥有这种物质是违法的。
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.
这些因素应仔细考虑，并告诫读者不要过度依赖此类前瞻性陈述。
Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021 and its most recent MD&A, which are available at . There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
尽管公司试图确定可能导致实际行动、事件或结果与前瞻性陈述中描述的大不相同的重要风险因素，但可能存在其他风险因素，导致行动、事件或结果与预期、估计或预期的不同。识别可能影响财务业绩的风险和不确定因素的其他信息包含在公司提交给加拿大证券监管机构的文件中，包括日期为2021年4月15日的修订和重新发布的上市声明以及最新的MD&A，这些文件可在上查阅。不能保证前瞻性陈述将被证明是准确的，因为实际结果和未来事件可能与前瞻性陈述中预期的大不相同。
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问